Genmab — Februar 2021
-
I like the “..., though” at the end!
-
Roche don‘t expect Glofitamab to get to front line then? In yes, big advantage for Epcoritamab...
-
Epcoritamab is much better than Mosunetuzumab, really promissing now. They must have safety issues with Glofitamab then?
-
Okay, but why wouldn‘t they mention their most promissing and potent cd3/cd20? Strange...
-
Glofitamab is an investigational CD20xCD3 T-cell engaging bispecific antibody designed to target CD20 on the surface of B-cells and CD3 on the surface of T-cells. This dual targeting activates and redirects a patient’s existing T-cells to engage and eliminate target B-cells by releasing cytotoxic proteins into the B-cells. Glofi is based on a novel structural format which we call ‘2:1’, which refers to the structure of the antibody.
-
I wonder if Genmab i working on something like this https://www.nature.com/articles/d41586-019-03495-3
-
-
E L - therefore it looks like Roche is planning for Mosunetuzumab for first line and Glofitamab for later lines
-
and we know Jan want to put Epcoritamab in first line, and Epcoritamab is much more efficiant than Mosunetuzumab, therefore big advantage for Genmab
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind